Skyline Medical Board of Directors

Working with the Skyline Medical Management Team, the Board of Directors is committed to governing the company to secure STREAMWAY Systems as a leading surgical fluid disposal system in hospitals and surgery centers. 

Advisory Board

Richard L. Gabriel


Mr. Gabriel was appointed to the Board of Directors on December 1, 2016. He has more than 40 years of relevant healthcare experience, including two decades of executive leadership and as a director and consultant to development-stage companies. In addition serving as chief operating officer of GLG Pharma since 2009, from 2003 until 2009 Mr. Gabriel was chief executive officer of DNAPrint Genomics and DNAPrint Pharmaceuticals. He is currently a director of Windgap Medical. Mr. Gabriel holds an MBA from Suffolk University in Boston, and a BS in Chemistry from Ohio Dominican College in Columbus.

Dr. Carl Schwartz

Executive Chairman of the Board

Dr. Schwartz was appointed to Skyline Medical’s board of directors in March 2016, and became interim president and chief executive officer in May 2016.   He has owned and managed dental groups in Michigan, beginning with one practice in 1966, and overseeing its expansion into a 14-office practice when he left the active practice of dentistry in 1988. He currently owns two dental practices, in Burton, Mich. and Grand Blanc, Mich.

In 1988 Dr. Schwartz joined a family business, becoming chief executive officer of Plastics Research Corporation, a Flint, Mich. manufacturer of structural foam molding, a low pressure injection molding process.  While there, he led its growth from $2 million in revenues and 20 employees, to its becoming the largest manufacturer of structural foam molding products under one roof in the U.S. with more than $60 million in revenues and 300 employees when he retired in 2001.

Dr. Schwartz previously served on the board of Delta Dental Corporation of Michigan, was a member of the Michigan Advisory Board for Liberty Mutual Insurance and was a member of the Board of Trustees of the Museum of Contemporary Art in Florida.

He holds B.A. and D.D.S. degrees from the University of Detroit.

Thomas J. McGoldrick

Chairman of the Board

In May 2016, Mr. McGoldrick was elected Chairman of the Board. He has served as a director of the Company since 2005. Prior to that, he served as CEO of Monteris Medical Inc. from November 2002 to November 2005. He has been in the medical device industry for over 30 years and was co-founder and CEO of Fastitch Surgical in 2000. Fastitch is a start-up medical device company with unique technology in surgical wound closure. Prior to Fastitch, Mr. McGoldrick was President and CEO of Minntech from 1997 to 2000. Minntech was a $75 million per year publicly traded (NASDAQ-MNTX) medical device company offering services for the dialysis, filtration and separation markets. Prior to employment at Minntech from 1970 to 1997, he held senior marketing, business development and international positions at Medtronic, Cardiac Pacemakers, Inc. and Johnson & Johnson. Mr. McGoldrick is on the board of directors of two other start-up medical device companies.

Andrew P. Reding


Mr. Reding is an executive with extensive experience in sales and marketing of capital equipment for the acute care markets. He has served as a director of the Company since 2006 and he is currently the President and CEO of TRUMPF Medical Systems, Inc., a position he has held since April 2007. Prior to that, he was Director of Sales at Smith & Nephew Endoscopy; he also served as Vice President of Sales and Director of Marketing with Berchtold Corporation from 1994 to 2006. His experience encompasses the marketing and sales of architecturally significant products for the operating room, emergency department and the intensive care unit. Mr. Reding has successfully developed high quality indirect and direct sales channels, implemented programs to interface with facility planners and architects and developed GPO and IDN portfolios. Mr. Reding holds a bachelor’s degree from Marquette University and an MBA from The University of South Carolina.

Timothy A. Krochuk


Mr. Krochuk is a co-founder and Managing Director of GRT Capital Partners, LLC, an investment adviser based in Boston, and is a Portfolio Manager and Managing Partner for the GRT BioEdge Ventures Fund, a fund focused on equity investments in privately held, emerging healthcare and biopharmaceutical companies. Prior to starting GRT Capital Partners in 2001, Mr. Krochuk became the youngest diversified portfolio manager in the history of Fidelity and was responsible for the development, programming and implementation of investment models used by mutual funds with more than $20 billion in assets under management.

He currently serves as Chief Executive Officer of CHP Clean Energy, a full-service provider of biogas powered combined heat and power systems for wastewater treatment facilities with anaerobic digesters, which he founded in 2009.  He also serves on the Board of Directors of Windgap Medical and Flatirons Bank.

Mr. Krochuk holds an AB in Economics from Harvard College, a Chartered Financial Analyst designation, an Executive Masters Professional Director Certification from the American College of Corporate Directors and is an active member of the Board of the Massachusetts General Hospital President’s Council.

J. Melville Engle


Mr. Engle has worked in the healthcare industry for the past three decades.  Since 2012 he has served as President and Chief Executive Officer of Engle Strategic Solutions, a consulting company focused on CEO development and coaching, senior management consulting, corporate problem-solving and strategic and operational planning. He is Chairman of the Board of Windgap Medical, Inc., a start-up medical device firm focused on unique drug delivery applications, and has held executive positions at prominent companies including Chairman and Chief Executive Officer at ThermoGenesis Corp. (NASDAQ: KOOL), Regional Head/Director, North America at Merck Generics (XETRA:  MRK.  Darmstadt, Germany), President and Chief Executive Officer of Dey, L.P. and Senior Vice President, U.S. Sales at Allergan.

In addition to ThermoGenesis, he has served on the Board of Directors of several public companies, including Oxygen Biotherapeutics (NASDAQ: OXBT) and Anika Therapeutics (NASDAQ: ANIK).

Mr. Engle holds a BS in Accounting from the University of Colorado Boulder and a MBA in Finance from the University of Southern California.  He has served as a Trustee of the Queen of the Valley Medical Center Foundation, and a Board Member of the Napa Valley Community Foundation and the Napa College Foundation all in Napa, Calif., and as Vice Chair of the Thunderbird Global Council at the Thunderbird School of Global Management in Glendale, Ariz.